Current Event

Overview
Conference Program
PDF Download
Press Pass
Request Brochure

Arrive early and attend the Third Annual
Drug Repositioning Summit

October 6-7, 2008
Boston, MA

Accelerating Proof of Concept


	Conference Proceeding CD Now Available Single Copy - $250.00Site License - $995.00	Speaker Presentations Poster Abstracts and More!

Driving a More Productive and Cost-Effective Drug Development Process
With increasing resource pressure, drug developers need to make more effective and informed go/no-go decisions as early as possible in the drug development process. This allows the best compounds to move ahead with adequate resource support. By doing more of the right experiments, drug developers will face fewer surprises as drugs move into the more expensive later stages of the development process. Biomarkers, advanced bio-imaging and other tools are increasingly being used as important approaches to creating more effective decision making processes. Leading drug discovery and development companies are increasingly reorganizing their drug development process and programs to take advantage of new tools and techniques to improve ROI on Drug Development dollars and focus resources on the most promising candidates.

Featured Speakers:

Jan Van Gelder, Ph.D., Head,Preformulation, Eli Lilly and Company
Charles Gombar, Ph.D., Vice President, R+D Strategy and Business Improvement, Wyeth Pharmaceuticals
Victor Sandor, M.D., Global Product Head, Executive Director, Oncology, Clinical Development, AstraZeneca Pharmaceuticals
Dongzhou (Jeffery) Liu, Ph.D., M.Sc., M.B.A., Assistant Director, New Products Research & Development, GlaxoSmithKline
John Gilly, Ph.D., Deputy Director, Biopharmaceutical Development Program, SAICFrederick/ NCI-Frederick

Learn from Leading Practitioners How to Build a More Effective Drug Discovery and Development Process:

Advanced Proof-of-Concept Tools and Approaches
Moving Beyond the Phase Trial Model
Measuring Targets, Pathways and Impacts
Case Studies of New Proof-of-Concept Approaches and Programs
Understanding Candidate “Mechanisms-of-Action”
Risk-Sharing Models for Early Drug Development
Implementing New Drug Development Process Models
In-vitro and in-vivo Validation

Proof-of-Concept Tools, Techniques and Technologies:

FDG-PET Imaging
Biomarkers in Early Stage Drug Development
Gene Expression Approaches and Case Studies
Metabolomics Profiling
Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI)
Combination Protocols
Magnetic Resonance Spectroscopy (MRS)
Genetic Profiling to Stratify Patient Populations
Pharmacokinetics

Scientific Advisory Committee:
Charles Gombar, Ph.D., Vice President, R+D Strategy and Business Improvement, Wyeth Pharmaceuticals
Paul L. Domanico, Ph.D., President, Paul Domanico Consulting, LLC
Mark Watson, Ph.D., Associate Director, Biology, Gemin X Pharmaceuticals Canada, Inc.
Stephen Donahue, M.D., Senior Vice President, Clinical Development, Ore Pharmaceuticals, Inc.
Geert Kolvenbag, Ph.D., M.D., Executive Director, Development, Emerging Oncology and Infection Brands, AstraZeneca Pharmaceuticals, Inc.

Co-located Event:

Drug Repositioning Summit

October 6-7, 2008 | Boston, Massachusetts
Click here for updated conference information

Discounted Joint Pricing Options Available!